#merck
merck
276 views
4 Discussing
Hot
Latest
🚨 Our manager and Merck announce major progress in a personalized cancer vaccine using mRNA technology
In a notable development in the field of cancer treatment, Moderna and Merck have announced positive results from their Phase 3 trial of a personalized cancer vaccine based on mRNA technology.
The concept is different from traditional vaccines:
The vaccine is designed specifically for each patient based on the genetic mutations found within the tumor, with the aim of helping the immune system recognize and attack cancer cells with greater precision.
According to the announcement, the study included 1,137 patients with high-risk skin cancer. The vaccine was used together with Merck’s Keytruda after the tumor was surgically removed.
📌 The reported results showed:
• A significant reduction in the risk of cancer recurrence
• A lower chance of the disease spreading to other parts of the body
Moderna hopes to move forward toward bringing the treatment to market after completing the necessary regulatory procedures.
📈 The news strongly impacted the companies’ shares:
Merck reached new record levels, while Moderna’s stock jumped sharply, with gains of more than 180% during the recent upward surge, trading above $181 in after-hours trading according to the figures shared in connection with the news.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
In a notable development in the field of cancer treatment, Moderna and Merck have announced positive results from their Phase 3 trial of a personalized cancer vaccine based on mRNA technology.
The concept is different from traditional vaccines:
The vaccine is designed specifically for each patient based on the genetic mutations found within the tumor, with the aim of helping the immune system recognize and attack cancer cells with greater precision.
According to the announcement, the study included 1,137 patients with high-risk skin cancer. The vaccine was used together with Merck’s Keytruda after the tumor was surgically removed.
📌 The reported results showed:
• A significant reduction in the risk of cancer recurrence
• A lower chance of the disease spreading to other parts of the body
Moderna hopes to move forward toward bringing the treatment to market after completing the necessary regulatory procedures.
📈 The news strongly impacted the companies’ shares:
Merck reached new record levels, while Moderna’s stock jumped sharply, with gains of more than 180% during the recent upward surge, trading above $181 in after-hours trading according to the figures shared in connection with the news.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
Log in to explore more content